How Scientists Are Deploying Two Experimental Drugs Against the Rare Bundibugyo Ebola Strain

As health officials grapple with a fast-moving outbreak of the rare Bundibugyo ebolavirus in the Democratic Republic of Congo, the global medical community is launching an unprecedented scientific counter-offensive. Next week, the World Health Organization will initiate a major clinical trial to test two experimental therapeutics directly in the outbreak zone. The mobilization represents a critical shift in how global health agencies respond to rare pathogens, moving beyond mere containment to active, rapid clinical intervention.[1][2]

The urgency of the trial is driven by the stark realities on the ground. Since the outbreak was declared in mid-May, the virus has infected at least 1,094 people and claimed 277 lives, primarily in the DRC's northeastern Ituri province. WHO Director-General Tedros Adhanom Ghebreyesus recently warned that the outbreak is continuing to outpace the response, citing insufficient treatment capacity and the complexities of operating in an active conflict zone.[2][3]

The primary challenge facing responders is the specific nature of the pathogen. The current outbreak is driven by the Bundibugyo species of the ebolavirus, a rare strain first identified in Uganda in 2007. Unlike the more common Zaire ebolavirus—which caused the devastating 2014 West African epidemic—the Bundibugyo strain currently has no approved vaccines or licensed therapeutic treatments.[3]

The evolutionary differences between the strains are significant enough that existing medical countermeasures are rendered ineffective. The FDA-approved Ervebo vaccine and the Inmazeb monoclonal antibody cocktail are highly specific to the Zaire strain. Because their molecular targets do not perfectly align with the Bundibugyo virus, frontline health workers have been forced to rely entirely on early, aggressive supportive care to manage symptoms.[5]

To bridge this critical therapeutic gap, the upcoming clinical trial will evaluate two distinct experimental drugs: the monoclonal antibody cocktail MBP134 and the antiviral medication remdesivir. The trial aims to enroll between 500 and 1,000 patients, testing whether these candidates can reduce mortality when administered either individually or in combination.[1][2]

The logistics of the trial require massive international coordination. The effort is being spearheaded by the WHO in partnership with the DRC's National Institute for Biomedical Research (INRB), the Alliance for International Medical Action (ALIMA), and Oxford University. The United States government and Gilead Sciences have donated the necessary doses of the experimental treatments to ensure the trial can proceed without delay.[1][3]

The first arm of the trial will focus on MBP134, an investigational drug developed by Mapp Biopharmaceutical. MBP134 is a cocktail of two specific monoclonal antibodies—ADI-15878 and ADI-23774—that were originally isolated from a human survivor of the 2014 Zaire ebolavirus outbreak. Through a process called affinity maturation, researchers engineered these antibodies to broaden their neutralizing activity.[5][7]

The mechanism behind MBP134 makes it a uniquely powerful candidate. The two antibodies target highly conserved, non-overlapping epitopes on the ebolavirus glycoprotein—the molecular key the virus uses to enter human cells. By binding to these specific sites, MBP134 directly inhibits glycoprotein-mediated membrane fusion, effectively locking the virus out of the host's cells.[5][7]

Because these specific binding sites remain nearly identical across different viral strains, MBP134 functions as a "pan-ebolavirus" therapeutic. Laboratory and animal studies have demonstrated that it can neutralize all known pathogenic ebolaviruses, including Zaire, Sudan, and Bundibugyo. In a few isolated cases, including the recent medical evacuation of an infected American physician, MBP134 has already been administered under compassionate use protocols.[7]

The second arm of the trial will evaluate remdesivir, an antiviral drug developed by Gilead Sciences that gained global prominence during the COVID-19 pandemic. While monoclonal antibodies work by blocking the virus from entering cells, remdesivir operates internally. It functions as a polymerase inhibitor, disrupting the viral replication machinery once the pathogen has already breached the cell membrane.[1]

Virologists have noted that remdesivir may be uniquely suited to combat the Bundibugyo strain. Previous laboratory studies have shown that the Bundibugyo ebolavirus replicates more slowly than the Zaire strain, largely due to intrinsic differences in its polymerase complex. This slower replication cycle makes the virus highly susceptible to polymerase inhibitors.[6]

In specialized biosafety level 2 laboratory models, post-infection treatment with remdesivir demonstrated a significantly greater inhibitory effect against the Bundibugyo virus than it did against the Zaire strain. By stalling the already-slowed replication process, the antiviral drug gives the patient's natural immune system a crucial window of time to mount a defense and clear the infection.[6]

The clinical trial is designed to be highly adaptive. Vasee Moorthy, who leads the WHO's research and development blueprint arm, noted that the final number of enrolled patients will depend on the real-time efficacy of the therapeutics. If the data quickly shows that one drug, or the combination of both, drastically reduces mortality, the trial can pivot to prioritize the most effective treatment protocol.[2]

Conducting a rigorous clinical trial in the Ituri province presents immense operational hurdles. The region is characterized by ongoing armed conflict, population displacement, and fragile healthcare infrastructure. Over the past five weeks, the WHO and its partners have rapidly scaled up capacity, expanding from fewer than 10 treatment beds to over 500, and increasing testing capacity from 30 tests a day to more than 3,000.[2][3]

Community engagement remains a cornerstone of the trial's potential success. Health officials are working closely with local leaders to ensure transparency regarding the experimental nature of the treatments. The WHO has emphasized that the primary goal is not just data collection, but ensuring that affected communities have immediate access to the therapeutics if they prove safe and efficacious.[2]

The speed at which these trials are being deployed marks a significant evolution in outbreak management. Historically, clinical trials for rare pathogens took months or years to organize, often beginning only after an outbreak had naturally subsided. The ability to launch a structured, multi-drug trial while the Bundibugyo outbreak is still active provides a rare opportunity to gather definitive clinical data.

If successful, the trial could yield the world's first proven treatments for the Bundibugyo ebolavirus, fundamentally altering the prognosis for future outbreaks. More broadly, validating a pan-ebolavirus therapeutic like MBP134 would provide global health agencies with a universal countermeasure, eliminating the need to develop bespoke drugs for every emerging strain of the virus.[5][7]